98%
921
2 minutes
20
Clinical Relevance: Primary open-angle glaucoma is a major public health concern, particularly in Africa. Identifying population-specific risk factors for the disease will enable eye health clinicians to more precisely identify persons at risk for the disease.
Background: Ghana has a high prevalence of primary open-angle glaucoma. This study compared anterior segment ocular variables associated with primary open-angle glaucoma between a glaucomatous and non-glaucomatous Ghanaian population which may provide more insight into the aetiology of the disease.
Methods: Central corneal thickness, corneal diameter, corneal volume, anterior chamber angle, anterior chamber depth, and anterior chamber volume measurements were extracted from Pentacam results of 356 persons with primary open-angle glaucoma (mean age: 62.84 ± 14.59) and 311 controls (mean age: 60.80 ± 9.09). Intraocular pressure was measured using Goldmann applanation tonometry. Analysis of variance was used to compare means the measured ocular variables among the primary open-angle glaucoma and control groups. Cohen's d effect sizes and multivariate logistic regression were used to determine the primary open-angle glaucoma effect sizes and associations between primary open-angle glaucoma and the measured variables.
Results: Thinner central corneal measurements were moderately associated with severe primary open-angle glaucoma (aOR = 0.59; 95% CI: 0.40-0.87). Lower corneal volume measurements were associated with moderate primary open-angle glaucoma (aOR = 0.63; 95% CI: 0.40-0.99) and highly associated with severe primary open-angle glaucoma (aOR = 0.47; 95% CI: 0.32-0.70). Elevated intraocular pressure was highly associated with all stages of primary open-angle glaucoma (aOR > 4.02), with the strength of this association increasing with severity of primary open-angle glaucoma.
Conclusion: Risk factors for different stages of severity of primary open-angle glaucoma are revealed. Thinner central corneas, lower corneal volumes, and elevated intraocular pressure measurements are risk factors for primary open-angle glaucoma in Ghanaians.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/08164622.2025.2546004 | DOI Listing |
Vestn Oftalmol
September 2025
Krasnov Research Institute of Eye Diseases, Moscow, Russia.
Primary open-angle glaucoma (POAG) is characterized by chronic progressive damage to the retinal ganglion cell layer (GCL) and their axons, leading to gradual visual function loss. Currently, the gold standards for structural and functional assessment of the retina in glaucoma are static automated perimetry (SAP) and optical coherence tomography (OCT). However, in clinical practice, data from SAP and OCT may be insufficient to reliably determine the stage of glaucomatous optic neuropathy, monitor its progression, or differentiate it from other causes of visual dysfunction.
View Article and Find Full Text PDFVestn Oftalmol
September 2025
OOO Diagnosticheskij tsentr Zreniye, Saint Petersburg, Russia.
Objective: This study evaluated the effect of sequential therapy with different dosages of Mexidol on the stabilization of glaucomatous optic neuropathy (GON) in patients with primary open-angle glaucoma (POAG).
Material And Methods: The study included 80 patients (160 eyes) with stage II and III POAG, randomized into three groups comparable by age, gender, and distribution of glaucoma stage. All patients received sequential therapy with Mexidol (14 days parenterally followed by 90 days orally).
Front Pharmacol
August 2025
Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, IL, United States.
4-Phenylbutyrate (4-PBA), initially recognized for treating urea cycle disorders, has emerged as a potent therapeutic agent with broad-spectrum potential. As a chemical chaperone, 4-PBA modulates protein folding and reduces endoplasmic reticulum stress. 4-PBA has demonstrated efficacy in treating ocular herpes simplex virus type 1 (HSV-1) infection and HSV-1-induced encephalitis, highlighting its potential as a novel anti-herpetic therapy.
View Article and Find Full Text PDFGraefes Arch Clin Exp Ophthalmol
September 2025
Department of Ophthalmology, Shimane University Faculty of Medicine, Shimane, Japan.
Purpose: To evaluate the impact of prostaglandin-associated periorbitopathy (PAP) severity on the surgical outcomes of trabeculectomy (LEC) and Ahmed Glaucoma Valve (AGV) implantation in patients with primary open-angle glaucoma.
Methods: In this propensity score-matched retrospective cohort study, a total of 106 eyes with uncontrolled glaucoma were included. Postoperative follow-ups were conducted at 1, 3, 6, 9, and 12 months.
Ophthalmol Glaucoma
September 2025
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, England; Discipline of Clinical Ophthalmology and Eye Health, University of Sydney, Sydney, New South Wales, Australia.
Purpose: To compare the long-term safety of MicroShunt implantation with trabeculectomy in eyes with primary open-angle glaucoma (POAG).
Methods: This was a 3-year observational extension of a 2-year prospective randomized trial comparing clinical outcomes of MicroShunt implantation with trabeculectomy, both augmented with mitomycin C. Adverse events (AEs), intraocular pressure (IOP), and IOP-lowering medication use were recorded 36, 48, and 60 months after initial randomization.